Have you or your loved ones been diagnosed with cardiogenic shock?

You may be eligible to participate in a cardiogenic shock clinical trial.

Have you or your loved ones been diagnosed with cardiogenic shock? You may be eligible to participate in a cardiogenic shock clinical trial.

What is a clinical trial? Is participating in a clinical trial right for you? Learn more

Cardiogenic Shock Clinical Trial
NCT02301819 | Interventional
Na Homolce Hospital
Sponsored by
Na Homolce Hospital

Have you or your loved ones been diagnosed with cardiogenic shock?

You may be eligible to participate in a cardiogenic shock clinical trial.

Have you or your loved ones been diagnosed with cardiogenic shock? You may be eligible to participate in a cardiogenic shock clinical trial.

Active not recruiting

Male & Female

18 Years +

This study has recruited 122 Participants

Eligible patients with severe cardiogenic shock will be randomized to one of the two arms: immediate ECMO therapy or early conservative therapy. In the invasive group, veno-arterial ECMO will be implanted according to the local practice with flow settings to ensure sufficient tissue perfusion. With the exception of ECMO implantation in the invasive group, all other diagnostic and therapeutic procedures will be done according to the current standard of care at the tertiary cardiovascular center, including other cardiovascular interventions (i.e. percutaneous coronary intervention or cardiac surgery). Implantation of other mechanical support devices including ECMO in the primary conservative group is allowed in the case of shock progression with rise of serum lactate by 3 mmol/L in comparison with the lowest value during the past 24 hours. Follow-up include visits at 30 days, 6 moths and 12 months.